Business Context and Reporting Period
Spruce Biosciences, Inc. (SPRB), a Delaware corporation, filed this Form 8-K on February 8, 2023, to report the entry into a Material Definitive Agreement. The Company is an emerging growth company with principal executive offices in South San Francisco, California.
Key Financial Metrics and Transaction Details
This filing details a private placement transaction rather than periodic financial results. Key metrics related to the transaction include:
- Expected Gross Proceeds: Approximately $53.6 million.
- Securities Issued:
- 16,116,000 shares of Common Stock.
- 800,000 Pre-Funded Warrants (exercise price $0.01).
- 12,687,000 Standard Warrants (exercise price $3.96).
- Purchase Price: $3.17 per share for Common Stock and Standard Warrants; $3.16 per Pre-Funded Warrant.
- Warrant Terms: Standard Warrants are exercisable for 75% of the aggregate shares purchased by the investor and have a five-year term.
- Transaction Fees: Placement agent fees are approximately 5% of aggregate gross proceeds.
Material Changes and Transaction Structure
The Company entered into a Securities Purchase Agreement with certain institutional investors, including existing holders of more than 5% of outstanding Common Stock (Abingworth, HealthCap, Novo Holdings A/S, RiverVest Venture Partners, and Rock Springs Capital). SVB Securities LLC acted as the lead placement agent. The transaction is expected to close on or before February 17, 2023, subject to customary conditions. The securities were sold pursuant to exemptions under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on operational outlook. Key contingencies and risks include:
- Closing Conditions: The transaction is subject to customary closing conditions.
- Registration Obligations: The Company must file registration statements within 30 days of closing to register the resale of securities. Failure to do so may result in cash penalties.
- Dilution: The issuance of new shares and warrants will result in dilution to existing shareholders.
- Representations: The Purchase Agreement contains representations and warranties intended to allocate risk between parties and should not be relied upon as statements of fact regarding the Company's condition.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $53.6 million gross proceeds.
- Monitor the filing of the registration statement for resale of securities within the 30-day post-closing deadline.
- Review the impact of the 16.1 million new shares and 12.7 million warrants on fully diluted share count.
- Confirm the final exercise prices of the warrants in case of any stock splits or combinations prior to closing.